Full-Time

FP&a Manager

Posted on 9/27/2025

Maravai LifeSciences

Maravai LifeSciences

51-200 employees

Offers oligonucleotide synthesis and immunohistochemistry

Compensation Overview

$129k - $137k/yr

+ Company Equity + Bonus Participation + Company Sponsored Benefits

San Diego, CA, USA

In Person

On-site role; based in San Diego, CA.

Category
Finance & Banking (1)
Requirements
  • Bachelor’s degree in Finance, Accounting, Economics, or related field with at least 5 years of progressive experience in FP&A or Corporate Finance
  • MBA or CPA and public company and/or Life Sciences industry experience preferred
  • Strong expertise in financial modeling, scenario planning, and data-driven decision support
  • Deep understanding of income statement, balance sheet, and cash flow dynamics
  • Exceptional communication and presentation skills with ability to influence stakeholders at all levels
  • Advanced proficiency in Excel; experience with ERP systems (e.g., NetSuite) and BI tools (Tableau, Power BI) preferred
  • Demonstrated ability to work independently while collaborating effectively and mentoring others.
Responsibilities
  • Lead portions of the annual operating plan, rolling forecasts, and long-range strategic plans. Partner cross-functionally to gather inputs, align assumptions, and ensure consistency with corporate objectives.
  • Act as a trusted finance partner to business and functional leaders, delivering insights on revenue, expenses, and profitability. Translate analysis into clear, actionable recommendations that influence operational and strategic decisions.
  • Build and maintain financial models to evaluate performance, assess investments, and support margin improvement initiatives. Conduct scenario and sensitivity analyses to guide decision-making.
  • Prepare and present monthly and quarterly financial reports (P&L, balance sheet, cash flow). Deliver variance analyses, identify performance drivers, and recommend actions to senior stakeholders.
  • Enhance forecasting, reporting, and data processes through automation, improved controls, and increased data integrity. Drive efficiencies that enable scalable growth.
  • Provide guidance and coaching to junior team members by reviewing analyses, sharing best practices, and supporting professional development. Foster a culture of accountability, collaboration, and continuous improvement.
  • Performs other functions and duties as required.

Maravai LifeSciences provides tools and services for life sciences research and bioproduction, including supplying oligonucleotides for PCR, next-generation sequencing (NGS), and gene editing, as well as immunohistochemistry for cancer research, serving academic institutions, biotechnology firms, and pharmaceutical companies. Oligonucleotide synthesis creates short DNA or RNA strands used in PCR, sequencing, and genome editing workflows; immunohistochemistry uses labeled antibodies to detect proteins in tissue samples. It differentiates itself by combining investment and operational support to incubate and scale life science companies while offering essential research tools. Its goal is to catalyze the development of life science companies to advance human health by providing capital, expertise, and essential research tools.

Company Size

51-200

Company Stage

IPO

Headquarters

San Diego, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • TriLink base revenue grows 15% YoY in Q1 2026 from non-COVID mRNA demand.
  • Molecular Assemblies acquisition in January 2025 enhances enzymatic DNA synthesis.
  • Alphazyme cuts Linea RNAP costs 70% via Applied DNA scale-up in 2024.

What critics are saying

  • Moderna and BioNTech vertically integrate capping by Q4 2026, eliminating TriLink sales.
  • GenScript's CleanScript kits with 20% higher efficiency steal share in Pfizer trials.
  • Thermo Fisher launches integrated mRNA kits in April 2025, eroding CleanCap dominance.

What makes Maravai LifeSciences unique

  • CleanCap® achieves >95% co-transcriptional capping efficiency versus enzymatic methods.
  • CleanCap M6 analog boosts mRNA potency with highest protein expression in 2023.
  • TriLink bundles CleanCap with NTPs, ModTail, and enzymes for streamlined synthesis.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Company Equity

Fertility Treatment Support

Family Planning Benefits

401(k) Retirement Plan

Paid Vacation

Company News

Valley Times-News
Mar 6th, 2025
MRVI INVESTOR ALERT: Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

MRVI INVESTOR ALERT: Maravai LifeSciences Holdings, Inc. investors with substantial losses have opportunity to lead Class Action lawsuit.

Tidewater News
Mar 1st, 2025
MRVI INVESTIGATION NOTICE: Investigation Launched into Maravai LifeSciences Holdings, Inc. and Attorneys Encourage Investors with Substantial Losses or Witnesses with Relevant Information to Contact Law Firm

SAN DIEGO, March 1, 2025 /PRNewswire/ - The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) focused on whether the company and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.

Investing.com
Jan 28th, 2025
Maravai LifeSciences expands mRNA manufacturing with new acquisition

SAN DIEGO - Maravai LifeSciences, Inc. (NASDAQ: MRVI), a $796 million market cap company known for supplying life science reagents and services, has announced the acquisition of intellectual property and assets from Molecular Assemblies, Inc.

LifeCare News
Dec 5th, 2024
Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors

Maravai LifeSciences appoints R. Andrew Eckert as Chairman of the Board of Directors.

San Diego Business Journal
Nov 25th, 2024
Maravai to Acquire Officinae Bio

More recently, Maravai acquired the molecular biology enzyme provider Alphazyme, LLC, in 2022.

INACTIVE